Bibliography
- BONEU B: Les nouveaux medicaments antithrom-botiques. Sang Thrombose Vaisseaux: Utilisation des traite-ments antithrombotiques en pratique médicale courante (1996) Suppl.:39–43.
- LEONE-BAY A, LEIPOLD H, AGARWAL R, RIVERA T, BAUGHMAN RA: The evolution of an oral heparin dos-ing solution. Drugs of the Future (1997) 22:885–891.
- ERIKSSON BI, WILLE-JORGENSEN P, KALEBO P et al.: A comparison of recombinant hirudin with a low-molecular weight to prevent thromboembolic compli-cations after total hip replacement. New Engl. J. Med. (1997) 337:1329–1335.
- BAJUSZ S, BARABAS E, TOLNAY P, SZELL E, BAGDY D: In-hibition of thrombin and trypsin by tripeptide alde-hydes. Int. J. Peptide Protein Res. (1978) 12:217–221.
- HUSSAIN MA, KNABB R, AUNGST BJ, KETTNER C: Antico-agulant activity of a peptide boronic acid thrombin in-hibitor by various routes of administration in rats. Peptides (1991) 12:1153–1154.
- FEVIG JM, BURIAK J, CACCIOLA J et al: Rational design of boropeptide thrombin inhibitors with greater selec-tivity over complement factor I. In: Abstracts of the 212th American Chemical Society National Meeting, Division of Medicinal Chemistry (1996) :127.
- CALLAS D, FAREED J: Comparative pharmacology of site directed antithrombin agents. Implication in drug development. Thrombosis Haemostasis (1995) 74:473–481.
- VINCENT M, PASCARD C, CÉSARIO M et al: Synthesis and conformational studies of zabicipril (5 9650-3), a po-tent inhibitor of angiotensin converting enzyme. Tet-rahedron Lett. (1992) 33:7369–7372.
- PORTEVIN B, BENOIST A, RÉMOND G et al.: New prolyl endopeptidase inhibitors : in vitro and in vivo activi-ties of azabicyclo[2.2.2]octane, azabicyclo[2.2.1]hep-tane, and perhydroindole derivatives. J. Med. Chem. (1996) 39:2379–2391.
- RUPIN A, MENNECIER P, LILA C, DE NANTEUIL G, VER-BEUREN TJ: Selection of S 18326 as a potent and selec-tive boronic acid direct thrombin inhibitor. Thrombosis Haemostasis (1997) 78:1221–1227.
- DE NANTEUIL G, GLOANEC P, LILA C et al.: New tripepti-dic thrombin inhibitors. Influence of P2 and P3 resi-dues on activity and selectivity. Bioorg Med. Chem. (1995) 3:1019–1024.
- RUPIN A, MENNECIER P, DE NANTEUIL G, VERBEUREN TJ: S 18326 is a potent boroarginic anti-thrombin agent which does not interfere with flbrinolysis. Thrombosis Haemostasis (1995) 73:1309.
- RUPIN A, VALLEZ MO, MENNECIER P, COURCHAY C, DE NANTEUIL G, VERBEUREN TJ: The new orally active thrombin inhibitor S 18326 does not possess inflam-matory effects at antithrombotic doses. Thrombosis Haemostasis (1997) Suppl.:545.
- RUPIN A, VALLEZ MO, MENNECIER P, DE NANTEUIL G, VERBEUREN TJ: The direct thrombin inhibitor S 18326 has additional activity on tissue factor/factor Vila and high efficacy on venous thrombosis. Thrombosis Hae-mostasis (1997) Suppl.:95.
- MATTESON DS, MAJUMDAR D: Homologation of bo-ronic esters to a-chloro boronic esters. Organometallics (1983) 2:1529–1535.
- VERBEUREN TJ, RUPIN A, SIMONET S, VALLEZ MO, DE NANTEUIL G: Anti-thrombotic properties of S 18326. A potent orally active tripeptide boronic acid thrombin inhibitor. Thrombosis Haemostasis (1995) 73:1310.
- VERBEUREN TJ, VALLEZ MO, RUPIN A, VERSLUYS D, SI-MONET S, DE NANTEUIL G: Efficacy of the direct throm-bin inhibitor S 18326 in a canine model of venous thrombosis. Thrombosis Haemostasis (1997) 75 Suppl.:96.